Across TCGA pan-cancer cohorts, ZBTB3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB3 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZBTB3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB3 expression acts as an unfavorable survival marker.
HNSC, KIRP, and COAD are the cancer types where ZBTB3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.